Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: Current patterns of care

Cancer

Volumn 92, Issue 6, 2001, Pages 1354-1367

  Link, Brian K ^a   Thomas Budd, G ^b   Scott, Shane ^a   Dickman, Elliot ^c   Paul, David ^d   Lawless, Grant ^e,f   Lee, Martin W ^g   Fridman, Moshe ^h   Ford, Jon ^f   Carter, William B ^f  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Meridia Cancer Institute   (United States)

^d Affiliated Oncologists Ltd   (United States)

^e Highmark Blue Cross Blue Shield   (United States)

^f AMGEN INC   (United States)

^g PARK NICOLLET INSTITUTE   (United States)

^h AMF Consulting   (United States)

Author keywords

Breast carcinoma; Chemotherapy; Dose intensity; Practice patterns; Quality of care

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GROWTH FACTOR; METHOTREXATE; PREDNISONE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER STAGING; COMORBIDITY; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE QUALITY; HOSPITALIZATION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMORBIDITY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; LYMPH NODES; METHOTREXATE; MIDDLE AGED;

EID: 0035883625     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010915)92:6<1354::AID-CNCR1458>3.0.CO;2-P     Document Type: Article

References (31)

1. Geographic variation in the treatment of myocardial infarction: The Cooperative Cardiovascular Project
2. Cancer statistics, 2000
3. Adjuvant CMF in breast cancer: Comparative 5-year results of 12 versus 6 cycles
4. Adjuvant chemotherapy after conservative surgery plus irradiation versus modified radical mastectomy: Analysis of drug dosing and toxicity
5. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer: The Ludwig Breast Cancer Study Group
6. Two months of doxorubicine-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15
7. A randomized trial of 15 versus 30 weeks of adjuvant chemotherapy in high risk breast cancer patients: Results after a median follow-up of 9.1 years
8. Prognostic factors in metastatic breast cancer treated with combination chemotherapy
9. A comparison of cyclophosphamide, Adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: A Southeastern Cancer Study Group project
10. A randomized comparative trial of Adriamycin versus methotrexate in combination drug therapy
11. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive noses: Ten-year results
12. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up
13. Analysis of dose intensity for adjuvant chemotherapy trials in Stage II breast cancer
14. The importance of dose intensity in chemotherapy of metastatic breast cancer
15. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: Summation dose-intensity
16. Dose and dose intensity of adjuvant chemotherapy for Stage II, node-positive breast carcinoma
17. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer
18. Re: Dose and dose intensity as determinants of outcomes in the adjuvant treatment of breast cancer
19. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential Paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC)
20. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18
21. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22
22. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25
23. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
24. Measuring comorbidity in older cancer patients
25. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives
26. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy
27. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy
28. Age-related patterns of care: Evidence against ageism in the treatment of early-stage breast cancer
29. CMF versus CAF with and without tamoxifen in high risk node negative breast cancer patients and a natural history follow-up study in low risk node negative patients: First results of Intergroup trial INT 0102
30. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer
31. Systemic treatment for early breast cancer by hormonal, systemic or immune therapy: In 133 randomized trials with 31,000 recurrences and 24,000 deaths among 75,000 women